Recent Articles
Page 1 of 7
January 5, 2021
Immuneering Completes Oversubscribed $62 Million Series B Financing
Financing to support advancement of Immuneering’s lead drug programs targeting cancers driven by alterations in the RAS/MAPK pathway and pipeline development of earlier programs in neuroscience and immuno-oncology.
November 10, 2020
Biomarkers Show the Power of Contexualization
In this Genetic Engineering & Biotechnology News article by Richard A. Stein, Immuneering’s Head of Neuroscience J.L. Ross, Ph.D. discusses the company’s integration of biomarkers with bioinformatic, proteomic, and gene signature information…
October 26, 2020
Silencing gene expression to cure complex diseases
In this article by Zach Winn, Immuneering co-founder and CEO Ben Zeskind discusses his journey from MIT undergraduate to biotech entrepreneur. He speaks to the company’s decade-plus of experience helping…
August 11, 2020
Immuneering to Present at Oppenheimer’s Private Life Sciences Company Call Series
CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) — Immuneering Corporation today announced the company’s participation in Oppenheimer’s Private Life Sciences Company Call Series taking place virtually August 17-19, 2020. Immuneering…
June 25, 2020
Immuneering Enters Collaboration with Astex Pharmaceuticals to Identify Novel Therapeutic Targets in Central Nervous System Disorder Using Disease Cancelling Technology
CAMBRIDGE, Mass., June 25, 2020 (GLOBE NEWSWIRE) — Immuneering Corporation today announced a collaboration between its neuroscience division, known as Alleo Labs, and Astex Pharmaceuticals (UK), a wholly owned subsidiary…
March 25, 2020
IMMUNEERING EXPANDS ONCOLOGY SCIENTIFIC ADVISORY BOARD WITH EXPERTS IN KEY CANCER SIGNALING PATHWAY
Oncology Scientific Advisory Board to support advancement of Immuneering’s drug programs modulating the RAS/MAPK signaling pathway in cancer CAMBRIDGE, Mass. – March 25, 2020 – Immuneering Corporation today announced…
January 30, 2020
Immuneering CEO interviewed by Alex Keown of BioSpace, Inc
Published: Jan 28, 2020 By Alex Keown In drug development, assets are often aimed at a specific disease target or pathway, similar to a bullet fired from a…
January 27, 2020
WSJ Pro: Venture Capital publishes article about Immuneering Corporation
IMMUNEERING RAISES $20 MILLION FOR NEW DRUG-DISCOVERY EFFORT Company formed in 2008 also provides services to pharmaceutical companies By Brian Gormley Venture capitalists are betting $20 million that…
January 22, 2020
IMMUNEERING RAISES $20 MILLION IN OVERSUBSCRIBED SERIES A FUNDING
FINANCING TO FUND IMMUNEERING’S PIPELINE INCLUDING PROGRAMS IN CANCER CACHEXIA, NEXT-GENERATION KRAS INHIBITION AND THE RAF-MEK PATHWAY, ALL DRIVEN BY ITS DISEASE CANCELLING TECHNOLOGY CAMBRIDGE, Mass. – Jan. 22,…
January 17, 2020
The Bio Report Podcast
On this episode of The Bio Report podcast Immuneering co-founder and CEO Ben Zeskind discusses the company’s evolution from its roots in bioinformatics, movement into drug development, and the proprietary…
Page 1 of 7
